Decisions 12th January 2016

At the meeting that took place on 5th July, the folllowing decisions were agreed.


New Drug Requests


Olsalazine (TLS Bue)

  • Approved for inclusion onto the formulary for patients with ulcerative colitis who in addition have proximal constipation.

Peppermint oil enemas (TLS Red)

  • Approved for inclusion onto the formulary for patients with glaucoma undergoing colonoscopy.

Infliximab (TLS Red)

  • Approved for inclusion onto the formulary for the treatment of steroid refractory colitis secondary to ipilimumab therapy.   

Not Approved

Levonorgestrel intrauterine system, Levosert

  • The JFG did not approve the inclusion of Levosert at this current time due to a lack of clinical or financial benefit proposed over current formulary options. 

More information required

Rivaroxaban - DVT post limb fracture and immobilisation

  • The JFG agreed that there is a clear rationale for using rivaroxaban, an oral treatment and there are clear benefits for patients.  However, the current national guidelines suggest that there is insufficient evidence to recommend oral treatment in place of a LMWH.  The local haematologists’ views are to be sought and application brought back to next meeting.

Cangrelor - patients undergoing PCI who have suffered out of hospital arrest in whom oral therapy is not feasibile or desirable

  • The JFG required further information regarding the exact patient cohort and treatment pathway for these patients.

Shared Care Protocols/TLS Change in Status 


  • Approved to change to amber 1 month once SCP agreed.  

Lisdexamfetamine (paediatric)

  • Agreed to change to amber 3 months once SCP agreed.



Last updated by: on 28-04-2016 11:25